SeaSpine® Announces 50,000th NanoMetalene® Implantation
CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the implantation of the 50,000th NanoMetalene® interbody device. NanoMetalene is a proprietary surface technology for interbody implants that incorporates a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide a bone-friendly titanium surface with 360 degree coverage, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for postoperative imaging.
“Our innovative NanoMetalene surface technology continues to be foundational to our Fusion Engineered focus,” stated Dennis Cirino, Senior Vice President of Global Spinal Systems. “In just over two years, we more than doubled the number of NanoMetalene implants used in surgery. Our team takes great pride in positively impacting every single patient life by seeking ways to achieve better outcomes and each surgeon’s ultimate fusion goal. SeaSpine remains committed to advancing the development of differentiated surface materials and novel designs, highlighted by the introduction of Reef Topography™ and the WaveForm 3D implant portfolio. The success of our NanoMetalene interbody portfolio demonstrates that leveraging science and clinical data is instrumental in driving the optimization of fusion postoperatively.”
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the design goals of surface materials and technologies and ability of provide intended benefits; and the Company’s commitment to advancing the development of differentiated surface materials and novel designs. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of products to perform as designed and intended and to meet the needs of surgeons and patients; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact
- Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
- Cost, Access are Biggest Barriers to OUD Recovery, But Telemedicine Can Help, According to New Report from Bicycle Health
- Sienna Senior Living Announces Closing of Common Share Offering for Gross Proceeds of Approximately $86 Million